



PTC Therapeutics, Inc.

100 Corporate Court

South Plainfield, NJ 07080

908.222.7000

www.ptcbio.com

22 October 2021

Re: Clinical Trial Results Posting

Product:	Ataluren (PTC124)
Protocol number	PTC124-GD-031-MPS
EudraCT number	2015-003105-41
Protocol Title	CNS Unmet Medical Need in Mucopolysaccharidosis: A Phase 2 Safety and Pharmacokinetics Study of Ataluren (COMPASS)
Sponsor:	PTC Therapeutics, Inc.
EU Sponsor Contact:	Medical Information, PTC Therapeutics, Inc., +011 44 1-866-562-4620, medinfo@ptcbio.com

Reference is made to the PTC124-GD-031-MPS study for Ataluren (PTC124), which was prematurely terminated. The global end of trial for PTC124-GD-031-MPS occurred on 09 March 2017.

In this study, which was conducted only in the United Kingdom (UK), 1 single participant was screened but failed screening. Therefore, no patient actually participated in the study, globally. As a result, no clinical study results are available.

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) was notified of the premature termination of this study on 26 October 2020.

We trust that you will find the documentation satisfactory. Please do not hesitate to contact us should you require any further information.

Yours faithfully,

DocuSigned by:
S Andeh
98BDC9E30393477...

Sophia Andeh

Head of Global Medical Information and Medical Capabilities

Medical Information,

PTC Therapeutics, Inc.,

+011 44 1-866-562-4620

medinfo@ptcbio.com